SCHEMBL3532268

SCHEMBL3532268

Cn1c(CCc2ccc(F)cc2)c(C2CC2)c(=O)n1-c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 8/20 0.41
HSD11B1 P28845 3/20 0.37
HRH3 Q9Y5N1 1/20 0.35
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR7 P34969 1/20 0.34
HTR6 P50406 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
PKM P14618 1/20 0.34
CYP2C19 P33261 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ACHE P22303 1/20 0.34
GAA P10253 1/20 0.34
MCHR1 Q99705 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530825 0.84 HSD11B1 (0.41) CCR3HSD11B1ALDH1A1CYP3A4MAPT
SCHEMBL3528063 0.84 HSD11B1 (0.38) CCR3HSD11B1HTR7MEN1KMT2A
SCHEMBL3530750 0.80 MCHR1 (0.38) HRH3ALDH1A1MAPTMCHR1
SCHEMBL3527793 0.79 MAPT (0.37) CCR3ALDH1A1CYP3A4MAPTCYP2C9
SCHEMBL3527433 0.78 HSD11B1 (0.41) CCR3HSD11B1HTR7MAPTMEN1
SCHEMBL3530986 0.78 MEN1 (0.47) CCR3HSD11B1HTR7ALDH1A1MEN1
SCHEMBL3528656 0.75 HSD11B1 (0.41) HSD11B1HTR2AHTR7ALDH1A1MAPT
SCHEMBL3531866 0.72 HSD11B1 (0.40) HSD11B1CYP3A4MAPT
SCHEMBL3526739 0.70 HSD11B1 (0.46) HSD11B1ALDH1A1CYP3A4MAPTCYP2C9
SCHEMBL3528744 0.69 HSD11B1 (0.43) CCR3HSD11B1HTR7CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US claimed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US claimed
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 CCR3 2775/4885HSD11B1 1/4885HRH3 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.